Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05783063 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

iTBS for Increased Appetite Induced by Antipsychotics

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 26, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 1, 2025 to Jun 1, 2026
    • Study completion date: Dec 1, 2025 to Aug 1, 2026
    • Site contacts updated at 1 of 2 sites
    v9
  2. Secondary endpoints: 12 to 29v8
  3. Eligibility criteria expanded, about 13 words
    • Secondary endpoints: 7 to 12
    • Site contacts updated at 1 of 2 sites
    v7
  4. Primary completion date: Aug 1, 2024 to Aug 1, 2025
    • Study completion date: Dec 1, 2024 to Dec 1, 2025
    • Secondary endpoints: details revised at 3 of 7 entries
    v6
  5. Study sites: 1 to 2v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 9 more changesShow less
    • Enrollment target: 40 to 60
    • Primary completion date: Dec 1, 2023 to Aug 1, 2024
    • Primary endpoints: 4 to 1
    • Study sites: 0 to 1
    • Study completion date: Mar 1, 2024 to Dec 1, 2024
    • Start date changed from estimate of Jun 1, 2023 to Aug 1, 2023
    • Secondary endpoints: 4 to 7
    • Eligibility criteria expanded, about 3 words
    • Study description shortened, about 2 words
  2. Start date: May 1, 2023 to Jun 1, 2023
    • Primary completion date: Feb 1, 2024 to Dec 1, 2023
    v3
  3. Study description shortened, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to healthy people. Conventional high-frequency rTMS have been used to treat people with obesity and showed certain effectiveness. However, studies involving schizophrenia patients and intermittent theta burst (iTBS) mode are rarely seen. The goal of this clinical trial is to evaluate the efficacy and safety of iTBS on ameliorating increased appetite induced by antipsychotics in people with schizophrenia.
Trial Details
NCT Number NCT05783063
Lead Sponsor Central South University
Conditions
(from sponsor)		 Schizophrenia
Related terms Body Weight, Schizophrenia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov